JAK inhibitor approved for the first time for the treatment of eczema, upatinib received EU approval for the fourth indication

On August 24, 2021, AbbVie announced that the European Commission (EC) approved its oral JAK inhibitor upadacitinib (upadacitinib, English trade name Rinvoq) to expand its indications for the treatment of suitable systemic For adults and adolescents over 12 years of age with moderate/severe atopic dermatitis, they can choose whether to use it in combination with topical corticosteroids (TCS)

Upatinib is a selective and reversible oral JAK inhibitor and is currently being studied in several immune-mediated inflammatory diseases

The Phase 3 trial project enrolled more than 2500 adults and adolescents with moderate/severe atopic dermatitis, and evaluated the efficacy and safety of upatinib as a single agent or in combination with TCS compared with placebo

In terms of safety, the most commonly reported adverse reactions (≥5%) in the 15 mg or 30 mg upatinib group were upper respiratory tract infection (25.

Reference materials:

[1] European Commission Approves Rinvoq® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis.

(The original text has been deleted)